Alemtuzumab in Sezary syndrome: efficient but not innocent


Ure U. B., Ar M. C., Salihoglu A., Guner S. I., Baran A., Oguz O., ...Daha Fazla

EUROPEAN JOURNAL OF DERMATOLOGY, cilt.17, sa.6, ss.525-529, 2007 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 6
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1684/ejd.2007.0269
  • Dergi Adı: EUROPEAN JOURNAL OF DERMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.525-529
  • İstanbul Üniversitesi Adresli: Evet

Özet

Mycosis fungoides is the most common form of cutaneous T-cell lymphomas. The related Sezary syndrome is a more aggressive form in which the skin is diffusely affected and the peripheral blood is involved. Although easily managed during its early phases, late-stage mycosis fungoides/Sezary syndrome is usually difficult to treat and becomes refractory to chemotherapy. Recently, promising case-based results have been obtained with alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that binds to CD52 cell surface antigens, in the treatment of advanced stage mycosis fungoides/Sezary syndrome. We report a case of Sezary syndrome treated successfully with alemtuzumab but who died of treatment-related infection.